Epidermal growth factor receptor expression in patients with ductal breast carcinoma. Comparison with clinicopathological factors and estrogen receptor status

1994 ◽  
Vol 1 (2) ◽  
pp. 63-69
Author(s):  
A Harlozinska ◽  
J K Bar ◽  
M Bebenek ◽  
P Kowalski ◽  
P Sedlaczek
Keyword(s):  
Estrogen Receptor ◽  
Epidermal Growth Factor Receptor ◽  
Lymph Node ◽  
Growth Factor ◽  
Breast Carcinoma ◽  
Growth Factor Receptor ◽  
Lymph Node Involvement ◽  
Node Involvement ◽  
Epidermal Growth ◽  
Er Expression

ABSTRACT Epidermal growth factor receptor (EGFR) and estrogen receptor (ER) status were immunohistochemically evaluated in 80 primary ductal breast carcinomas. The comparison between EGFR status and tumor grading, tumor size, lymph node involvement and age of patients was performed. EGFR expression was found in 87.5% of carcinoma samples and 46.3% of tumors were positive for ER staining. The inverse relationship between EGFR and ER expression was confirmed and it was evident that a high concentration of EGFR exceeding 25% of a tissue section may inhibit or significantly limit the ability to express ERs. EGFR presence was significantly associated with poorly differentiated tumors. No correlation was found between EGFR positivity and tumor size, lymph node involvement or age of patients. Our results indicate that EGFR status does not seem to be a valuable independent prognostic indicator, but that the combination of EGFR positivity (above 25% of a tissue section) accompanied by a low or undetectable level of ER expression should be considered as a potential marker of a poor prognosis in patients with ductal breast carcinoma.

Immunohistochemical and Clinicopathologic Characteristics of Invasive Ductal Carcinoma of Breast With Micropapillary Carcinoma Component

2005 ◽  
Vol 129 (10) ◽  
pp. 1277-1282 ◽  
Author(s):  
Mi-Jung Kim ◽  
Gyungyub Gong ◽  
Hee Jae Joo ◽  
Se-Hyun Ahn ◽  
Jae Y. Ro
Keyword(s):  
Estrogen Receptor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Breast Carcinoma ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Invasive Breast Carcinoma ◽  
Nodal Metastases ◽  
Micropapillary Carcinoma ◽  
Epidermal Growth

Abstract Context.—A micropapillary carcinoma (MC) component is generally considered to behave aggressively. Although several reports have described the prognostic significance of MC in breast carcinomas, immunohistochemical findings of MC, especially as compared to non-MC, are rarely described. Objective.—We compared clinicopathologic and immunohistochemical findings between 38 cases of invasive breast carcinoma with an MC component (IMC) and 217 cases of invasive breast carcinoma without an MC component (NIMC). Design.—We constructed a tissue microarray from 38 cases of IMC and performed immunohistochemical stainings for cytokeratin (CK) 7, CK20, estrogen receptor, progesterone receptor, p53, c-Erb-B2, CD34, CK5, epidermal growth factor receptor, and c-Kit in both MC and non-MC components. Results.—Cases with IMC were associated with greater tumor size, more frequent lymphovascular invasion, nodal metastases, greater mean numbers of positive lymph nodes, and higher stage than those with NIMC, but were not associated with poorer survival rates. On immunohistochemistry, only p53 reactivity was statistically different between MC and non-MC components in IMC cases. Estrogen receptor positivity tended to be lower in MC than non-MC, but the difference was not significant. Most of the MCs and non-MCs in IMC cases were positive for CK7, but none of them were positive for CK20, CK5, epidermal growth factor receptor, or c-Kit. Conclusions.—Based on the frequent nodal metastases and association with higher stage found in IMC as compared with NIMC cases, as well as higher p53 positivity and lower frequency of estrogen receptor expression, MC could be considered an aggressive histologic type of breast carcinoma. In both MC and non-MC components in IMC cases, no basallike immunostaining pattern was detected.

scholarly journals Monitoring the Crosstalk Between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 with PET

2020 ◽  
Vol 22 (5) ◽  
pp. 1218-1225
Author(s):  
I. F. Antunes ◽  
G. A. P. Hospers ◽  
J. W. A. Sijbesma ◽  
A. S. Boerema ◽  
A. van Waarde ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Estrogen Receptor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Ex Vivo ◽  
Acquired Resistance ◽  
Growth Factor Receptor ◽  
Targeted Treatment ◽  
Epidermal Growth ◽  
Er Expression

Abstract Purpose Ovarian cancer (OC) leads to poor survival rates mainly due to late stage detection and innate or acquired resistance to chemotherapy. Thus, efforts have been made to exploit the estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) to treat OC. However, patients eventually become resistant to these treatments as well. HER2 overexpression contributes to the acquired resistance to ER-targeted treatment. Trastuzumab treatment, on the other hand, can result in increased expression of ER, which, in turn, increases the sensitivity of the tumors towards anti-estrogen therapy. More insight into the crosstalk between ER and HER2 signaling could improve our knowledge about acquired resistance in ovarian cancer. The aim of this study was to evaluate whether PET could be used to detect changes in ER expression induced by HER2-targeted treatment in vivo. Procedures Male athymic nude mice were subcutaneously (sc) inoculated with 106 SKOV3 human ovarian cancer cells (HER2+/ER+). Two weeks after inoculation, tumor-bearing mice were treated intraperitoneally with either vehicle, the HER2 antibody trastuzumab (20 mg/kg, 2×/week), or the HER2-tyrosine kinase inhibitor lapatinib (40 mg/kg, 5 days/week) for 2 weeks. Thereafter, ER expression in the tumor was assessed by PET imaging with 16α-[18F]-fluoro-17β-estradiol ([18F]FES). Tumors were excised for ex vivo ER and HER2 measurement with Western blotting and immunohistochemistry. Results All treatments led to smaller tumors than vehicle-treated tumors. Higher [18F]FES maximum standardize tumor uptake (SUVmax) was observed in animals treated with trastuzumab (+ 29 %, P = 0.002) or lapatinib (+ 20 %, P = 0.096) than in vehicle-treated controls. PET results were in agreement with ex vivo analyses. Conclusion FES-PET imaging can detect changes in ER expression induced by HER2-targeted treatment and therefore can be used to investigate the crosstalk between ER and HER2 in a noninvasive manner.

Sign in / Sign up

Export Citation Format

Share Document